期刊
INTERNATIONAL JOURNAL OF CANCER
卷 144, 期 12, 页码 3146-3159出版社
WILEY
DOI: 10.1002/ijc.32058
关键词
neuroblastoma; MDM2 antagonists; idasanutlin (RG7388); RO6839921 (RG7775); temozolomide
类别
资金
- Cancer Research UK [C9380/A18084]
- Neuroblastoma UK
- Niamh's Next Step
- Sparks [11NCL05]
- Dubois Child Cancer Fund
- Italian Association for Cancer Research [IG14231IG18474]
- Little Princess Trust
- UK Children's Cancer & Leukaemia Group (CCLG)
High-risk neuroblastoma, a predominantly TP53 wild-type (wt) tumour, is incurable in >50% patients supporting the use of MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat neuroblastoma. This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921 (RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models. Detection of active idasanutlin using liquid chromatography-mass spectrometry and p53 pathway activation by ELISA assays and Western analysis showed peak plasma levels 1 h post-treatment with maximal p53 pathway activation 3-6 h post-treatment. RO6839921 and temozolomide, alone or in combination in mice implanted with TP53 wt SHSY5Y-Luc and NB1691-Luc cells showed that combined RO6839921 and temozolomide led to greater tumour growth inhibition and increase in survival compared to vehicle control. Overall, RO6839921 had a favourable pharmacokinetic profile consistent with intermittent dosing and was well tolerated alone and in combination. These preclinical studies support the further development of idasanutlin in combination with temozolomide in neuroblastoma in early phase clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据